{
    "5e2900368b3851296d000001_001": "",
    "5e2900368b3851296d000001_002": "orally active, non-peptide, competitive gonadotropin-releasing hormone",
    "5e2900368b3851296d000001_003": "an oral, nonpeptide gonadotropin-releasing hormone antagonist",
    "5e2900368b3851296d000001_004": "a new oral GnRH antagonist",
    "5e2900368b3851296d000001_005": "gonadotropin-releasing hormone (GnRH) receptor antagonist",
    "5e2900368b3851296d000001_006": "elagolix with 1.0 mg estradiol/0.5 mg norethindrone acetate",
    "5c7006037c78d6947100005d_001": "8 for central nervous system and vascular, 4 for renal and musculoskeletal",
    "5c7006037c78d6947100005d_002": "8 for central nervous system and vascular, 4 for renal and musculoskeletal",
    "5c7006037c78d6947100005d_003": "8 for central nervous system and vascular, 4 for renal and musculoskeletal",
    "5c7006037c78d6947100005d_004": "renal, immunological and hematologic active descriptors",
    "5c7006037c78d6947100005d_005": "Patients followed for a minimum of 3 visits, and without absence for a period > 18 consecutive months",
    "5e2894109499698331000002_002": "CNEFinder",
    "5e29f666aa19d74431000001_001": "Protein phosphatase 2A",
    "5e29f666aa19d74431000001_003": "Protein phosphatase 2A",
    "5e46da9c3f5415952900000a_001": "decreased global genome repair",
    "5e46da9c3f5415952900000a_002": "global genomic nucleotide excision repair (NER)",
    "5e46da9c3f5415952900000a_003": "global genomic nucleotide excision repair (NER)",
    "5e46da9c3f5415952900000a_004": "",
    "5e2902688b3851296d000005_001": "IGF1R",
    "5e2902688b3851296d000005_002": "IGF-IR",
    "5e2902688b3851296d000005_003": "IGF-1",
    "5e2902688b3851296d000005_005": "IGF-1",
    "5e2902688b3851296d000005_007": "insulin-like growth factor I",
    "5c700c607c78d6947100005e_001": "",
    "5c700c607c78d6947100005e_002": "",
    "5c700c607c78d6947100005e_003": "",
    "5c700c607c78d6947100005e_004": "",
    "5e2b0d167d50947c2f000002_002": "acromelic frontonasal dysostosis",
    "5e2b0d167d50947c2f000002_003": "acromelic frontonasal dysostosis",
    "5e2b0d167d50947c2f000002_005": "",
    "5e29f6e0aa19d74431000002_002": "",
    "5e29f6e0aa19d74431000002_003": "",
    "5e29f6e0aa19d74431000002_004": "",
    "5e29f6e0aa19d74431000002_006": "cancers",
    "5e29f6e0aa19d74431000002_007": "cancers",
    "5e29f6e0aa19d74431000002_009": "",
    "5e29f6e0aa19d74431000002_010": "",
    "5e46e74e3f5415952900000b_001": "Pathogenic variants",
    "5e46e74e3f5415952900000b_002": "biallelic mutations in ERCC4. ERCC4 mutations",
    "5e46e74e3f5415952900000b_003": "Any mutations in XPA",
    "5e46e74e3f5415952900000b_004": "NER-defective",
    "5e46e74e3f5415952900000b_005": "mutations in the ERCC1 or ERCC4 genes",
    "5e2902e48b3851296d000006_001": "",
    "5e2902e48b3851296d000006_002": "",
    "5e2902e48b3851296d000006_003": "",
    "5e2902e48b3851296d000006_004": "",
    "5e2902e48b3851296d000006_006": "SLE",
    "5e2902e48b3851296d000006_007": "SLE",
    "5e2902e48b3851296d000006_008": "",
    "5e2902e48b3851296d000006_009": "influenza",
    "5e2902e48b3851296d000006_010": "influenza",
    "5c7019557c78d6947100005f_002": "",
    "5c7019557c78d6947100005f_004": "decreased expression",
    "5c7019557c78d6947100005f_005": "Type I",
    "5c7019557c78d6947100005f_008": "The IFN-I signature was positive in 57% of cSLE patients",
    "5c7019557c78d6947100005f_009": "The IFN-I signature was positive in 57% of cSLE patients",
    "5e2b253ffbd6abf43b000006_002": "AZD5153 was non-cytotoxic to the prostate epithelial cells",
    "5e29f959aa19d74431000004_002": "",
    "5e29f959aa19d74431000004_003": "",
    "5e46e8c13f5415952900000c_001": "",
    "5e46e8c13f5415952900000c_002": "",
    "5e46e8c13f5415952900000c_003": "",
    "5e46e8c13f5415952900000c_004": "cyclobutane pyrimidine dimers (CPDs) and pyrimidine-pyrimidone photoproducts",
    "5e2903978b3851296d000007_001": "erythropoiesis stimulating fusion protein",
    "5e2903978b3851296d000007_002": "a modified ActRIIB-Fc",
    "5e2903978b3851296d000007_003": "",
    "5e2903978b3851296d000007_004": "activin receptor type II-Fc fusion proteins",
    "5e2903978b3851296d000007_005": "activin inhibitors",
    "5e2903978b3851296d000007_007": "modified ActRIIB-Fc",
    "5e2903978b3851296d000007_008": "an activin-receptor trap that modifies transforming growth factor-\u03b2 signaling",
    "5e2903978b3851296d000007_009": "a novel fusion protein that blocks transforming growth factor beta",
    "5c701f4f7c78d69471000060_001": "chronic myeloid leukemia",
    "5c701f4f7c78d69471000060_002": "chronic myeloid leukemia",
    "5c701f4f7c78d69471000060_004": "chronic myeloid leukemia",
    "5c701f4f7c78d69471000060_005": "myeloproliferative diseases",
    "5c701f4f7c78d69471000060_006": "myeloproliferative diseases",
    "5c701f4f7c78d69471000060_007": "",
    "5c701f4f7c78d69471000060_009": "minimal residual disease",
    "5c701f4f7c78d69471000060_010": "minimal residual disease",
    "5c701f4f7c78d69471000060_012": "chronic myeloid leukemia",
    "5c701f4f7c78d69471000060_014": "",
    "5e2b3784fbd6abf43b000009_001": "implicated in late embryonic and postnatal mouse development",
    "5e29fb27aa19d74431000005_001": "hyperphosphorylation",
    "5e480909d14c9f295d000003_001": "evidence for excess cardiovascular disease or cancer mortality",
    "5e480909d14c9f295d000003_002": "evidence for excess cardiovascular disease or cancer mortality",
    "5e480909d14c9f295d000003_003": "",
    "5e2905da8b3851296d000009_001": "an APOC3 antisense oligonucleotide",
    "5e2905da8b3851296d000009_003": "an investigational inhibitor of apoC-III synthesis",
    "5e2905da8b3851296d000009_004": "New apo C-III antisense oligonucleotide drug",
    "5e2905da8b3851296d000009_005": "inhibits the production of the Apo C-III",
    "5e2905da8b3851296d000009_006": "targets apolipoprotein C-III",
    "5c70273c7c78d69471000061_001": "",
    "5c70273c7c78d69471000061_002": "neuropsychiatric and renal systems",
    "5c70273c7c78d69471000061_003": "neuropsychiatric and renal systems",
    "5c70273c7c78d69471000061_004": "neuropsychiatric and renal systems",
    "5c70273c7c78d69471000061_005": "",
    "5e2d7fabfbd6abf43b00000c_002": "rescues these effects",
    "5e29fc57aa19d74431000006_001": "sensitized ovarian carcinoma lines to cisplatin-mediated cell death",
    "5e29fc57aa19d74431000006_002": "sensitized ovarian carcinoma lines to cisplatin-mediated cell death",
    "5e480ccfd14c9f295d000005_001": "excellent indicator",
    "5e480ccfd14c9f295d000005_002": "",
    "5e480ccfd14c9f295d000005_003": "",
    "5e2906948b3851296d00000a_001": "rapidly evolving",
    "5e2906948b3851296d00000a_002": "maintenance monotherapy",
    "5e2906948b3851296d00000a_003": "in complete or partial response to platinum-based chemotherapy",
    "5e2906948b3851296d00000a_004": "approved",
    "5e2906948b3851296d00000a_005": "maintenance treatment of women with recurrent ovarian cancer",
    "5c72768a7c78d6947100006c_002": "moderately biased X-chromosome inactivation profile and presenting with mild intellectual delay and minor psychotic features. The low mutation rate",
    "5c72768a7c78d6947100006c_003": "moderately biased X-chromosome inactivation profile and presenting with mild intellectual delay and minor psychotic features. The low mutation rate",
    "5c72768a7c78d6947100006c_005": "There is an excess",
    "5e2d80cafbd6abf43b00000d_001": "analyzes two 4D spectra recorded using a single, fully protonated protein sample",
    "5e29fe76aa19d74431000007_001": "There were 29 patient entries over 7 dose escalations",
    "5e480da0d14c9f295d000006_001": "treatment option for uveal melanoma.",
    "5e480da0d14c9f295d000006_002": "",
    "5e480da0d14c9f295d000006_003": "treating head and neck paragangliomas",
    "5e480da0d14c9f295d000006_004": "treating head and neck paragangliomas",
    "5e290a268b3851296d00000d_001": "",
    "5e290a268b3851296d00000d_002": "not an effective treatment for recurrent glioblastoma",
    "5c72c9207c78d6947100007b_001": "",
    "5c72c9207c78d6947100007b_002": "Markov models",
    "5c72c9207c78d6947100007b_003": "combinatorial genome segmentation solely using information on combinations of epigenetic marks",
    "5e2deb35fbd6abf43b00001c_002": "CAGE",
    "5e2a046caa19d74431000008_002": "",
    "5e48136dd14c9f295d000008_001": "hemopoietic stem cells",
    "5e48136dd14c9f295d000008_002": "stem cells",
    "5e48136dd14c9f295d000008_003": "stem cells",
    "5e2ad60e76af173751000003_001": "a heterogeneous clinical condition defined by the presence of the vermiform appendix within an inguinal hernia sac",
    "5e2ad60e76af173751000003_002": "a rare disease where the appendix is found within an inguinal hernia sac",
    "5e2ad60e76af173751000003_003": "a rare disease where the appendix is found within an inguinal hernia sac",
    "5e2ad60e76af173751000003_004": "the incarceration of the vermiform appendix in the hernia sac",
    "5e2ad60e76af173751000003_006": "",
    "5c74266a7c78d694710000a2_001": "localization",
    "5c74266a7c78d694710000a2_002": "localization",
    "5c74266a7c78d694710000a2_003": "pre-spliceosomal assembly on microinjected splicing-competent precursor mRNA",
    "5c74266a7c78d694710000a2_004": "regulation of pre-mRNA splicing",
    "5c74266a7c78d694710000a2_005": "",
    "5c74266a7c78d694710000a2_006": "",
    "5c74266a7c78d694710000a2_008": "exosome inactivation",
    "5c74266a7c78d694710000a2_009": "splicing",
    "5c74266a7c78d694710000a2_010": "active transcription sites",
    "5e2e11a1fbd6abf43b000021_001": "",
    "5e2a04feaa19d74431000009_002": "",
    "5e482160d14c9f295d00000c_001": "",
    "5e482160d14c9f295d00000c_002": "",
    "5e482160d14c9f295d00000c_003": "",
    "5e2b07537d50947c2f000001_002": "Scalp arteriovenous malformations",
    "5e2b07537d50947c2f000001_003": "rare congenital extracranial vascular anomalies",
    "5e2b07537d50947c2f000001_004": "right temporal pre-auricular arteriovenous fistula",
    "5e2b07537d50947c2f000001_005": "rare arteriovenous malformations of the scalp",
    "5e2b07537d50947c2f000001_006": "arteriovenous fistulas",
    "5c74285c7c78d694710000a3_001": "the cytoplasm",
    "5c74285c7c78d694710000a3_002": "",
    "5c74285c7c78d694710000a3_003": "cytoplasmic",
    "5c74285c7c78d694710000a3_004": "",
    "5c74285c7c78d694710000a3_005": "cytoplasmic",
    "5c74285c7c78d694710000a3_007": "",
    "5c74285c7c78d694710000a3_008": "",
    "5e2e136bfbd6abf43b000023_002": "OncoPPi Portal",
    "5e2a080caa19d7443100000a_001": "AMPK/Sirt1",
    "5e482f08d14c9f295d00000d_001": "chemical decomposition of the water molecule into free radicals",
    "5e482f08d14c9f295d00000d_003": "the PCT processes that generate the DNA-damaging species against cancerous cells",
    "5e2b0d71fbd6abf43b000001_001": "determine expected disposition prior to surgery",
    "5e2b0d71fbd6abf43b000001_002": "",
    "5e2b0d71fbd6abf43b000001_003": "The RAPT accurately predicted discharge disposition for high- and low-risk patients in our cohort",
    "5e2b0d71fbd6abf43b000001_004": "The RAPT accurately predicted discharge disposition for high- and low-risk patients in our cohort",
    "5e2b0d71fbd6abf43b000001_005": "The RAPT accurately predicted discharge disposition for high- and low-risk patients in our cohort",
    "5e2b0d71fbd6abf43b000001_006": "",
    "5e2b0d71fbd6abf43b000001_007": "",
    "5c74305d7c78d694710000a4_001": "FUS variants with disease-associated amino acid substitutions or short deletions affecting nuclear localization signal (NLS)",
    "5c74305d7c78d694710000a4_002": "endoplasmic-reticulum-bound transcripts",
    "5c74305d7c78d694710000a4_003": "mRNAs",
    "5c74305d7c78d694710000a4_004": "cytoplasmic",
    "5c74305d7c78d694710000a4_005": "cytoplasmic",
    "5c74305d7c78d694710000a4_006": "noncoding RNAs (ncRNAs",
    "5c74305d7c78d694710000a4_007": "noncoding RNAs (ncRNAs",
    "5e2e1792fbd6abf43b000024_001": "TBC1D24",
    "5e2a0a02aa19d7443100000b_002": "first-in-class humanized antibody",
    "5e2a0a02aa19d7443100000b_003": "first-in-class humanized antibody",
    "5e48339fd14c9f295d00000e_001": "systematically review the effects of KI administration",
    "5e48339fd14c9f295d00000e_002": "",
    "5e48339fd14c9f295d00000e_003": "",
    "5e2b109cfbd6abf43b000002_001": "Length of stay, Acuity of admission, Comorbidity, and Emergency visits in the previous 6 months",
    "5e2b109cfbd6abf43b000002_002": "length of stay, acuity of admission, co-morbidities, and emergency department visits",
    "5e2b109cfbd6abf43b000002_003": "high risk of early readmission",
    "5e2b109cfbd6abf43b000002_004": "number of ED visits within six months",
    "5e2b109cfbd6abf43b000002_005": "Length of stay, Acute/emergent admission, Charlson comorbidity index score, Emergency department visits in previous 6 months",
    "5c7a4a31d774d04240000006_001": "",
    "5c7a4a31d774d04240000006_002": "",
    "5c7a4a31d774d04240000006_003": "multiple unresolved issues",
    "5c7a4a31d774d04240000006_004": "multiple unresolved issues",
    "5c7a4a31d774d04240000006_005": "PD-L1 expression is just one of many variables that may affect response to PD-1 blockade",
    "5c7a4a31d774d04240000006_006": "composition\u00a0and\u00a0amount\u00a0of inflammatory cells",
    "5c7a4a31d774d04240000006_007": "heterogeneity",
    "5c7a4a31d774d04240000006_008": "PD-L1 overexpression could not be currently considered a robust biomarker to tailor the immune checkpoint inhibitors treatment",
    "5c7a4a31d774d04240000006_009": "many patients with NSCLC",
    "5c7a4a31d774d04240000006_010": "a subpopulation of TNBC more likely to respond to chemotherapy",
    "5c7a4a31d774d04240000006_011": "better progression-free survival (HR: 0.69, 95% CI: 0.57-0.85) and better overall survival",
    "5c7a4a31d774d04240000006_013": "",
    "5c7a4a31d774d04240000006_014": "not with gender, primary site, or lymph node status",
    "5c7a4a31d774d04240000006_016": "fundamental differences in PD-L1 expression between NSCLC and gastroesophageal cancers",
    "5c7a4a31d774d04240000006_017": "complicated by a number of factors",
    "5c7a4a31d774d04240000006_020": "there are currently no consensus guidelines for the treatment of these neoplasms",
    "5c7a4a31d774d04240000006_021": "",
    "5c7a4a31d774d04240000006_022": "",
    "5e307a05fbd6abf43b000036_002": "",
    "5e307a05fbd6abf43b000036_004": "MAGeCK)",
    "5e2a0eb1aa19d7443100000c_001": "not in vitro",
    "5e48e0e0f8b2df0d49000001_002": "profoundly impacted",
    "5e48e0e0f8b2df0d49000001_003": "decrease in the major gut microbiota community Enterobacteriaceae",
    "5e2b1ed9fbd6abf43b000005_001": "",
    "5e2b1ed9fbd6abf43b000005_002": "Parkinson's disease",
    "5e2b1ed9fbd6abf43b000005_003": "",
    "5e2b1ed9fbd6abf43b000005_004": "",
    "5e2b1ed9fbd6abf43b000005_005": "Parkinson's disease",
    "5e2b1ed9fbd6abf43b000005_006": "",
    "5e2b1ed9fbd6abf43b000005_007": "",
    "5e2b1ed9fbd6abf43b000005_008": "Parkinson's disease",
    "5e2b1ed9fbd6abf43b000005_009": "",
    "5c7a4c35d774d04240000007_001": "",
    "5c7a4c35d774d04240000007_002": "",
    "5c7a4c35d774d04240000007_003": "",
    "5c7a4c35d774d04240000007_004": "non-small cell lung cancer",
    "5c7a4c35d774d04240000007_005": "",
    "5c7a4c35d774d04240000007_006": "",
    "5c7a4c35d774d04240000007_007": "",
    "5c7a4c35d774d04240000007_008": "",
    "5e30b56efbd6abf43b000037_002": "The adaptation of the CRISPR-Cas9 system",
    "5e2a1096aa19d7443100000e_001": "a modified mRNA encoding vascular endothelial growth factor A",
    "5e48edb1f8b2df0d49000002_001": "",
    "5e2b2c85fbd6abf43b000007_001": "Grade IV vestibular schwannoma",
    "5e2b2c85fbd6abf43b000007_002": "",
    "5e2b2c85fbd6abf43b000007_004": "vestibular schwannoma",
    "5e2b2c85fbd6abf43b000007_006": "vestibular schwannoma",
    "5c7a4ed5d774d04240000008_002": "",
    "5c7a4ed5d774d04240000008_003": "",
    "5c7a4ed5d774d04240000008_005": "",
    "5c7a4ed5d774d04240000008_006": "",
    "5c7a4ed5d774d04240000008_007": "",
    "5c7a4ed5d774d04240000008_008": "",
    "5e355e20fbd6abf43b000065_002": "lamin B1 (LMNB1)",
    "5e355e20fbd6abf43b000065_003": "lamin B1",
    "5e355e20fbd6abf43b000065_004": "lamin B1 (LMNB1)",
    "5e355e20fbd6abf43b000065_005": "LMNB1",
    "5e355e20fbd6abf43b000065_006": "LMNB1",
    "5e355e20fbd6abf43b000065_008": "lamin B1",
    "5e2a120c76af173751000001_002": "",
    "5e48efd9f8b2df0d49000004_001": "to enable the creation of the large radiotherapy cohorts required to exploit advances in genomics",
    "5e48efd9f8b2df0d49000004_002": "identification of genomic markers that are predictive for the development of adverse effects resulting from cancer treatment with radiation",
    "5e48efd9f8b2df0d49000004_004": "",
    "5e2f0afcfbd6abf43b000028_001": "VEGF-R",
    "5e2f0afcfbd6abf43b000028_002": "endothelial growth factor receptors 1, 2\u00a0and 3 tyrosine kinases.",
    "5e2f0afcfbd6abf43b000028_004": "VEGFR1-3",
    "5e2f0afcfbd6abf43b000028_005": "pan-VEGF",
    "5e2f0afcfbd6abf43b000028_006": "VEGF",
    "5c7a4fddd774d04240000009_001": "",
    "5c7a4fddd774d04240000009_002": "",
    "5c7a4fddd774d04240000009_003": "",
    "5c7a4fddd774d04240000009_004": "",
    "5c7a4fddd774d04240000009_005": "",
    "5e35c4ea9be68b5512000002_002": "accurately identifies individual gene targets, gene signatures, and cell states affected by individual perturbations and\u00a0their genetic interactions.",
    "5e2daaa2fbd6abf43b00000e_001": "selective adenosine A2A receptor",
    "5e48f2b6f8b2df0d49000005_001": "adverse late reactions after radiotherapy",
    "5e48f2b6f8b2df0d49000005_002": "severity of radiation toxicity",
    "5e2f906ffbd6abf43b00002c_001": "oral viscous lidocaine/ antacid \u00b1 anticholinergic",
    "5e2f906ffbd6abf43b00002c_002": "",
    "5e2f906ffbd6abf43b00002c_003": "",
    "5e2f906ffbd6abf43b00002c_004": "Benzocaine and Lidocaine",
    "5e2f906ffbd6abf43b00002c_005": "Benzocaine and Lidocaine",
    "5e2f906ffbd6abf43b00002c_006": "",
    "5e2f906ffbd6abf43b00002c_007": "liquid antacid, viscous lidocaine, and an anticholinergic",
    "5e2f906ffbd6abf43b00002c_008": "",
    "5c7f806d617e120c34000001_001": "unknown how many tumours express tumour specific antigen at all and whether these putative antigens are of unique specificity",
    "5c7f806d617e120c34000001_002": "unknown how many tumours express tumour specific antigen at all and whether these putative antigens are of unique specificity",
    "5c7f806d617e120c34000001_003": "tumour-associated antigens",
    "5c7f806d617e120c34000001_004": "melanoma-associated antigens",
    "5c7f806d617e120c34000001_005": "",
    "5c7f806d617e120c34000001_006": "",
    "5c7f806d617e120c34000001_007": "specificity residing in a population of bound peptides",
    "5c7f806d617e120c34000001_008": "tumour-specific CD4(+) T cells collaborate with macrophages and dendritic cells.",
    "5c7f806d617e120c34000001_009": "",
    "5c7f806d617e120c34000001_010": "",
    "5e35cb27158f994d3a000002_001": "5376 and 110 regulatory variants",
    "5e48f90bf8b2df0d49000006_001": "wide range of products",
    "5e48f90bf8b2df0d49000006_002": "minimize the risk of infection transmission through bone allografts",
    "5e48f90bf8b2df0d49000006_003": "to provide safety against disease transmission",
    "5e48f90bf8b2df0d49000006_004": "",
    "5e2f93bbfbd6abf43b00002e_001": "",
    "5e2f93bbfbd6abf43b00002e_002": "hypotension, back pain and a pulsatile abdominal mass",
    "5e2f93bbfbd6abf43b00002e_003": "abdominal pain, pulsatile abdominal mass and shock",
    "5e2f93bbfbd6abf43b00002e_004": "",
    "5e2f93bbfbd6abf43b00002e_005": "pain, hypotension, and a pulsatile mass",
    "5ca61b14ecadf2e73f00004f_001": "",
    "5ca61b14ecadf2e73f00004f_002": "",
    "5ca61b14ecadf2e73f00004f_004": "",
    "5ca61b14ecadf2e73f00004f_006": "knockdown of FoxA1 expression blocks the association of ER with chromatin and estrogen-induced gene expression",
    "5ca61b14ecadf2e73f00004f_008": "",
    "5ca61b14ecadf2e73f00004f_009": "",
    "5ca61b14ecadf2e73f00004f_010": "",
    "5ca61b14ecadf2e73f00004f_011": "suppressed its activation",
    "5ca61b14ecadf2e73f00004f_012": "suppressed its activation",
    "5e369c30b5b409ea53000001_002": "Our reconstruction method",
    "5e2dad57fbd6abf43b000010_001": "Extended-release amantadine (amantadine ER) is the first approved medication for the treatment of dyskinesia",
    "5e49032df8b2df0d49000008_001": "single technologist",
    "5e49032df8b2df0d49000008_002": "",
    "5e49032df8b2df0d49000008_004": "",
    "5e2f9596fbd6abf43b00002f_001": "European Society of Endocrinology",
    "5e2f9596fbd6abf43b00002f_002": "adrenal insufficiency and alacrima",
    "5e2f9596fbd6abf43b00002f_003": "",
    "5e2f9596fbd6abf43b00002f_004": "",
    "5e2f9596fbd6abf43b00002f_005": "",
    "5e2f9596fbd6abf43b00002f_006": "",
    "5ca61f17ecadf2e73f000050_001": "",
    "5ca61f17ecadf2e73f000050_002": "preexistence of a structural backbone poised to integrate novel regulatory inputs, and a highly adaptive transcriptional readout",
    "5ca61f17ecadf2e73f000050_003": "",
    "5ca61f17ecadf2e73f000050_004": "future activation is not always observed",
    "5ca61f17ecadf2e73f000050_006": "the amount of actively used enhancers is lower than previously anticipated",
    "5e369ecfb5b409ea53000002_002": "",
    "5e369ecfb5b409ea53000002_004": "",
    "5e2dadcffbd6abf43b000011_001": "hallucination, dizziness, orthostatic hypotension and pedal edema",
    "5e490d276d0a277941000001_001": "DNA damage linked to environmental mutagenic and cytotoxic agents",
    "5e2f9ceefbd6abf43b000033_001": "acetylsalicylic acid, hydrochlorothiazide (HCT), enalapril (ENA)",
    "5e2f9ceefbd6abf43b000033_002": "hydrochlorothiazide, aspirin, atorvastatin and either enalapril or valsartan",
    "5e2f9ceefbd6abf43b000033_003": "aspirin, valsartan, atorvastatin and hydrochlorthiazide",
    "5cc011e2a49efeb44c000001_001": "",
    "5cc011e2a49efeb44c000001_002": "",
    "5cc011e2a49efeb44c000001_003": "",
    "5cc011e2a49efeb44c000001_004": "co-localize in a small number of dense-staining perinuclear foci.",
    "5e36ad01b5b409ea53000006_002": "",
    "5e36ad01b5b409ea53000006_004": "",
    "5e36ad01b5b409ea53000006_005": "",
    "5e2dae57fbd6abf43b000012_001": "approximately twice the level",
    "5e2dae57fbd6abf43b000012_002": "higher",
    "5e4981e96d0a277941000009_001": "The reduction of the dose limit for eye lens from 150 to 20 mSv yr-1 must be implemented by EU member states by February 2018",
    "5e4981e96d0a277941000009_002": "updated lower occupational exposure limit",
    "5e4981e96d0a277941000009_003": "updated lower occupational exposure limit",
    "5e4981e96d0a277941000009_004": "European directive 2013/59/Euratom",
    "5e4981e96d0a277941000009_005": "European directive 2013/59/Euratom",
    "5e4981e96d0a277941000009_006": "The reduction of the dose limit for eye lens from 150 to 20 mSv yr-1 must be implemented by EU member states by February 2018",
    "5e2f972bfbd6abf43b000030_001": "",
    "5e2f972bfbd6abf43b000030_002": "",
    "5e2f972bfbd6abf43b000030_003": "",
    "5e2f972bfbd6abf43b000030_004": "homogentisic aciduria, ochronosis, and arthritis",
    "5e2f972bfbd6abf43b000030_005": "",
    "5e2f972bfbd6abf43b000030_006": "",
    "5e2f972bfbd6abf43b000030_007": "homogentisic aciduria, arthritis and ochronosis",
    "5cc0817da49efeb44c000002_001": "",
    "5cc0817da49efeb44c000002_002": "",
    "5cc0817da49efeb44c000002_003": "",
    "5cc0817da49efeb44c000002_004": "",
    "5cc0817da49efeb44c000002_005": "",
    "5e36d807b5b409ea5300000a_002": "facilitates the transfer of parental (H3-H4)2 tetramers to lagging-strand DNA at replication forks",
    "5e2dafccfbd6abf43b000013_001": "",
    "5e499c636d0a27794100000a_001": "tumor-targeted radionuclides",
    "5e499c636d0a27794100000a_002": "Noradrenaline Transporter Molecule (NAT) and Somatostatin Receptor (SSTR2)",
    "5e2f992cfbd6abf43b000031_001": "",
    "5e2f992cfbd6abf43b000031_002": "atenolol, ramipril, hydrochlorothiazide, and a statin",
    "5e2f992cfbd6abf43b000031_003": "",
    "5e2f992cfbd6abf43b000031_004": "aspirin",
    "5e2f992cfbd6abf43b000031_005": "ramipril, hydrochlorothiazide, atenolol, aspirin, and simvastatin",
    "5e2f992cfbd6abf43b000031_006": "folic acid",
    "5cd96eb2a49efeb44c000003_001": "",
    "5cd96eb2a49efeb44c000003_003": "SweeD",
    "5cd96eb2a49efeb44c000003_004": "SweeD",
    "5cd96eb2a49efeb44c000003_005": "SweeD",
    "5cd96eb2a49efeb44c000003_006": "SmileFinder",
    "5cd96eb2a49efeb44c000003_007": "OmegaPlus",
    "5cd96eb2a49efeb44c000003_008": "LD-based methods",
    "5cd96eb2a49efeb44c000003_010": "RAiSD",
    "5e36d924b5b409ea5300000b_002": "",
    "5e2db15cfbd6abf43b000014_001": "",
    "5e4adcbe6d0a277941000017_001": "",
    "5e4adcbe6d0a277941000017_002": "",
    "5e4adcbe6d0a277941000017_003": "predicts the absence of radioiodine uptake at pT-WBS in DTC patients with incomplete bio-chemical response to first RAIT.",
    "5e4adcbe6d0a277941000017_004": "",
    "5e4adcbe6d0a277941000017_005": ""
}
